loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 5722 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Grace

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    SERVICES

    EXCIPIENTS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Aspen API. More than just an API.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Grace (1)

    filter

    01 ORPHENADRINE CITRATE USP (1)

    filter

    01 U.S.A (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    W R GRACE AND CO -CONN

    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      ORPHENADRINE CITRATE USP

      PDF Supplier PDF
      URL Supplier Web Content
      5722
      Active
      1985-02-22
      Complete
      2015-12-16
      2013-07-05
      II
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for Drug Master Files (DMF) for 5722 of W R Grace And Co -conn

      Looking for Drug Master Files (DMF) for 5722 of W R Grace And Co -conn 1

      20

      W R Grace And Co -conn, based in U.S.A, is a pharmaceutical company.

      One of their notable products is ORPHENADRINE CITRATE USP, with a corresponding US DMF Number 5722.

      Remarkably, this DMF maintains an Active status since its submission on February 22, 1985, highlighting commitment to regulatory compliance.

      Their GDUFA DMF Review was successfully complete, with a review date of December 16, 2015, and payment made on July 05, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II

      Post Enquiry
      POST ENQUIRY